ARTG 459493GOURI Polycaprolactone Injectable Implant - Dermal tissue reconstructive material, synthetic polymer
ARTG ID: 459493 · LC & Partners Pty Ltd · Dexlevo Inc · Class III · Started August 14, 2024
Good Name: LC & Partners Pty Ltd - GOURI Polycaprolactone Injectable Implant - Dermal tissue reconstructive material, synthetic polymer
- Risk Class
- Class III
- Product Type
- Single Device Product
- ARTG Category
- General
- ARTG ID
- 459493
- Start Date
- August 14, 2024
- Effective Date
- August 14, 2024
- Name
- Dexlevo Inc
- Country
- South Korea
- Address
- 505 Daeryung Techno Town 5-cha 632 Seobusaet-gil, Geumcheon-gu, Seoul
It is indicated to be used for facial tissue augmentation for mid-to-deep dermal implantation for the correction of moderate to severe facial wrinkles and folds.
Access comprehensive regulatory information for GOURI Polycaprolactone Injectable Implant - Dermal tissue reconstructive material, synthetic polymer in the Australia medical device market through Pure Global AI's free TGA ARTG database. This Class III is registered under ARTG number 459493 and sponsored by LC & Partners Pty Ltd, manufactured by Dexlevo Inc in South Korea. The device registration started on August 14, 2024.
This page provides complete registration details including sponsor information, manufacturer details, and regulatory compliance data from the official Australia TGA ARTG medical device database. Pure Global AI offers free access to Australia's complete medical device registry with 131,000+ devices, helping global MedTech companies navigate TGA regulations efficiently.